Abstract
Acral lentiginous melanoma (ALM), described by Reed more than 30 years ago, has many unique characteristics. However, ALM is still a mysterious form of skin cancer. Of the four major subtypes of cutaneous melanoma (CM) worldwide, ALM is the rarest. Although ALM is the most common subtype of CM among Asians, Middle Easterners, and Africans, the absolute number of ALM cases is small. This is because CM is a rather rare skin cancer in Asia, Middle East, and Africa, compared to those in western countries. ALM occurs on the palms, soles, and nails as unexposed lesions. The pathogeneses of ALM remain unknown. Furthermore, ALM has a more advanced status at diagnosis, and the prognosis of ALM is the worst among all types of CM. Several reasons for the poor prognosis are proposed from various perspectives; however, they have not been ascertained. Therefore, there is need for further studies to understand the nature of ALM, establish its original diagnosis, and identify treatment modalities for ALM in the future.
References
Arrington JH 3rd, Reed RJ, Ichinose H, Krementz ET (1977) Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol 1:131–143
Ashida A, Takata M, Murata H, Kido K, Saida T (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124:862–868
Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, Uchiyama A, Ogawa E, Hayashi K, Koga H, Okuyama R (2012) Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci 66:240–242
Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L (2017) MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases. Clin Cancer Res 23:6120–6127
Balch CM (1990) Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer. Surgery 108:118–119
Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Desmond R (2001) Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 8:101–108
Banfield CC, Redburn JC, Dawber RP (1998) The incidence and prognosis of nail apparatus melanoma. A retrospective study of 105 patients in four English regions. Br J Dermatol 139:276–279
Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, Ariyan CE (2013) Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol 20:3618–3625
Blessing K, Kernohan NM, Park KG (1991) Subungual malignant melanoma: clinicopathological features of 100 cases. Histopathology 19:425–429
Boriani F, O’leary F, Tohill M, Orlando A (2014) Acral Lentiginous Melanoma – misdiagnosis, referral delay and 5 years specific survival according to site. Eur Rev Med Pharmacol Sci 18:1990–1996
Bradford PT, Goldstein AM, Mcmaster ML, Tucker MA (2009) Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986–2005. Arch Dermatol 145:427–434
Buchbinder EI, Sosman JA, Lawrence DP, Mcdermott DF, Ramaiya NH, Van Den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS (2015) Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer 121:4007–4015
Busam KJ, Iversen K, Coplan KC, Jungbluth AA (2001) Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 25:197–204
Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, Kuo TT, Yang CH (2004) Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res 14:537–541
Choi YD, Chun SM, Jin SA, Lee JB, Yun SJ (2013) Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses. J Am Acad Dermatol 69:700–707
Cirenajwis H, Lauss M, Ekedahl H, Torngren T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, Harbst K, Hayward NK, Jonsson G (2017) NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol 11:438–451
Clark WH Jr, Elder DE, Van Horn M (1986) The biologic forms of malignant melanoma. Hum Pathol 17:443–450
Clarkson JH, Mcallister RM, Cliff SH, Powell B (2002) Subungual melanoma in situ: two independent streaks in one nail bed. Br J Plast Surg 55:165–167
Cohen T, Busam KJ, Patel A, Brady MS (2008) Subungual melanoma: management considerations. Am J Surg 195:244–248
Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, Jonsson PE, Krysander L, Lindholm C, Ringborg U (2000) Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer 89:1495–1501
Cooper C, Arva NC, Lee C, Yelamos O, Obregon R, Sholl LM, Wagner A, Shen L, Guitart J, Gerami P (2015) A clinical, histopathologic, and outcome study of melanonychia striata in childhood. J Am Acad Dermatol 72:773–779
Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 8:246–252
Cronin KA, Lake AJ, Scott S (2018) Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 124:2785–2800
Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346
D’angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35:226–235
Daly JM, Berlin R, Urmacher C (1987) Subungual melanoma: a 25-year review of cases. J Surg Oncol 35:107–112
Davis EJ, Johnson DB, Sosman JA, Chandra S (2018) Melanoma: what do all the mutations mean? Cancer 124(17):3490–3499
Desai A, Ugorji R, Khachemoune A (2018) Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clin Exp Dermatol 43:117–123
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozon V, Long GV, Flaherty K (2017) Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:435–445
Duprat JP, Silva DC, Coimbra FJ, Lima IA, Lima EN, Almeida OM, Brechtbuhl ER, Landman G, Scramim AP, Neves RI (2005) Sentinel lymph node biopsy in cutaneous melanoma: analysis of 240 consecutive cases. Plast Reconstr Surg 115:1944–1951 discussion 1952–3
Durbec F, Martin L, Derancourt C, Grange F (2012) Melanoma of the hand and foot: epidemiological, prognostic and genetic features. A systematic review. Br J Dermatol 166:727–739
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters M, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, Mackenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, Mcmasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, Mckinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211–2222
Fernandes JD, Hsieh R, De Freitas LA, Brandao MA, Lourenco SV, Sangueza M, Nico MM (2015) MAP kinase pathways: molecular roads to primary acral lentiginous melanoma. Am J Dermatopathol 37:892–897
Finley RK 3rd, Driscoll DL, Blumenson LE, Karakousis CP (1994) Subungual melanoma: an eighteen-year review. Surgery 116:96–100
Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, Gavrielides M, Xing W, Gore M, Larkin J, Marais R (2014) The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res 27:835–838
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R (2008) Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 18:152–160
Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI (1998) Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124:203–210
Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Mansson-Brahme E, Ingvar C, Ringborg U (2011) 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 378:1635–1642
Green A, Mccredie M, Mackie R, Giles G, Young P, Morton C, Jackman L, Thursfield V (1999) A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control 10:21–25
Grotz TE, Glorioso JM, Pockaj BA, Harmsen WS, Jakub JW (2013) Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 153:535–541
Gumaste PV, Fleming NH, Silva I, Shapiro RL, Berman RS, Zhong J, Osman I, Stein JA (2014) Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? J Natl Compr Cancer Netw 12:1706–1712
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904–2909
Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (2015) Vital signs: melanoma incidence and mortality trends and projections – United States, 1982–2030. MMWR Morb Mortal Wkly Rep 64:591–596
Haneke E (2006) Surgical anatomy of the nail apparatus. Dermatol Clin 24:291–296
Haneke E (2012) Ungual melanoma – controversies in diagnosis and treatment. Dermatol Ther 25:510–524
Hayashi K, Uhara H, Koga H, Okuyama R, Saida T (2012) Surgical treatment of nail apparatus melanoma in situ: the use of artificial dermis in reconstruction. Dermatol Surg 38:692–694
Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, Theaker J, Bliss JM, Thomas JM, Group, U. K. M. S., British Association of, P., Reconstructive, Aesthetic, S. & The Scottish Cancer Therapy, N (2016) Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 17:184–192
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545:175–180
Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R (2014) Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 5:3401
High WA, Quirey RA, Guillen DR, Munoz G, Taylor RS (2004) Presentation, histopathologic findings, and clinical outcomes in 7 cases of melanoma in situ of the nail unit. Arch Dermatol 140:1102–1106
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O’day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van Den Abbeele AD, Demetri GD, Fisher DE (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31:3182–3190
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150:251–263
Holmstrom H (1992) Surgical management of primary melanoma. Semin Surg Oncol 8:366–369
Hong JW, Lee S, Kim DC, Kim KH, Song KH (2014) Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Ann Dermatol 26:195–202
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959
Hutchinson J (1886) Melanosis often not black: melanotic whitlow. Br Med J 1:491–494
Imakado S, Sato H, Hamada K (2008) Two cases of subungual melanoma in situ. J Dermatol 35:754–758
Imbulgoda A, Heng DY, Kollmannsberger C (2014) Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res 201:165–184
Ishihara K, Saida T, Otsuka F, Yamazaki N (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33–41
Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, Furue M, Uchi H (2015) Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? J Am Acad Dermatol 72:71–77
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014–4023
Jeon SY, Hong JW, Lee S, Oh SY, Hong YS, Kim KH, Song KH (2014) Long-term survival analysis and clinical follow-up in acral lentiginous malignant melanoma undergoing sentinel lymph node biopsy in korean patients. Ann Dermatol 26:177–183
Jin SA, Chun SM, Choi YD, Kweon SS, Jung ST, Shim HJ, Yun SJ (2013) BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. J Invest Dermatol 133:579–582
Jung HJ, Kweon SS, Lee JB, Lee SC, Yun SJ (2013) A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol 149:1281–1288
Jung JY, Roh HJ, Lee SH, Nam K, Chung KY (2011) Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot. Dermatol Surg 37:1245–1251
Kapteijn BA, Nieweg OE, Liem I, Mooi WJ, Balm AJ, Muller SH, Peterse JL, Valdes Olmos RA, Hoefnagel CA, Kroon BB (1997) Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 4:156–160
Karakousis CP (1998) Therapeutic node dissections in malignant melanoma. Ann Surg Oncol 5:473–482
Kato T, Suetake T, Sugiyama Y, Tabata N, Tagami H (1996) Epidemiology and prognosis of subungual melanoma in 34 Japanese patients. Br J Dermatol 134:383–387
Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM (2017) Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Investig 97:1063–1071
Kenady DE, Brown BW, Mcbride CM (1982) Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery 92:615–618
Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, Lauret P, Verola O, Auclerc G, Harper P, Banzet P (2003) Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 97:1941–1946
Kim JY, Jung HJ, Lee WJ, Kim Do W, Yoon GS, Kim DS, Park MJ, Lee SJ (2011) Is the distance enough to eradicate in situ or early invasive subungual melanoma by wide local excision? From the point of view of matrix-to-bone distance for safe inferior surgical margin in Koreans. Dermatology 223:122–123
Kim YC, Lee MG, Choe SW, Lee MC, Chung HG, Cho SH (2003) Acral lentiginous melanoma: an immunohistochemical study of 20 cases. Int J Dermatol 42:123–129
Koga H, Saida T (2011) Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions. Arch Dermatol 147:741–743
Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684–1691
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, Mccusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006–1014
Kuchelmeister C, Schaumburg-Lever G, Garbe C (2000) Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol 143:275–280
Kunishige JH, Brodland DG, Zitelli JA (2012) Surgical margins for melanoma in situ. J Am Acad Dermatol 66:438–444
Lang J, Mackie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125:575–579
Lazar A, Abimelec P, Dumontier C (2005) Full thickness skin graft for nail unit reconstruction. J Hand Surg Br 30:194–198
Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776–784
Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J (2017) Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res 27:524–532
Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW (2014) TERT promoter mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol 41:504–508
Lin YC, Chang YM, Ho JY, Lin HC, Tsai YM, Chiang CP, Wang WM, Gao HW (2013) C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people. Am J Dermatopathol 35:569–575
Lino-Silva LS, Dominguez-Rodriguez JA, Aguilar-Romero JM, Martinez-Said H, Salcedo-Hernandez RA, Garcia-Perez L, Herrera-Gomez A, Cuellar-Hubbe M (2016) Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype. Ann Surg Oncol 23:4189–4194
Liu JF, Zhao LR, Lu LJ, Chen L, Liu ZG, Gong X, Liu B (2014) Limb salvage surgery following resection of a melanoma: foot and ankle reconstruction using cutaneous flaps. Oncol Lett 8:1966–1972
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246
Luk NM, Ho LC, Choi CL, Wong KH, Yu KH, Yeung WK (2004) Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese. Clin Exp Dermatol 29:600–604
Lv J, Dai B, Kong Y, Shen X, Kong J (2016) Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep 6:31432
Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F, Fontanini G (2015) Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 467:177–184
Maekawa T, Komine M, Murata S, Ohtsuki M (2014) Surgical treatment of subungual melanoma: a case treated with bone splitting of the distal phalanx. J Dermatol 41:944–946
Meng X, Huang Z, Teng F, Xing L, Yu J (2015) Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 41:868–876
Metzger S, Ellwanger U, Stroebel W, Schiebel U, Rassner G, Fierlbeck G (1998) Extent and consequences of physician delay in the diagnosis of acral melanoma. Melanoma Res 8:181–186
Meyer T, Merkel S, Gohl J, Hohenberger W (2002) Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 28:424–430
Minagawa A, Omodaka T, Okuyama R (2016) Melanomas and mechanical stress points on the plantar surface of the foot. N Engl J Med 374:2404–2406
Moehrle M, Metzger S, Schippert W, Garbe C, Rassner G, Breuninger H (2003) “Functional” surgery in subungual melanoma. Dermatol Surg 29:366–374
Moon KR, Choi YD, Kim JM, Jin S, Shin MH, Shim HJ, Lee JB, Yun SJ (2018) Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features. J Invest Dermatol 138:933–945
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, Mckinnon JG, Wang HJ, Elashoff R, Faries MB, Group, M (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599–609
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399
Nakamura Y, Fujisawa Y, Teramoto Y, Sato S, Yamada K, Sekine K, Fujimoto M, Otsuka F, Yamamoto A (2014) Tumor-to-bone distance of invasive subungual melanoma: an analysis of 30 cases. J Dermatol 41:872–877
Nakamura Y, Ohara K, Kishi A, Teramoto Y, Sato S, Fujisawa Y, Fujimoto M, Otsuka F, Hayashi N, Yamazaki N, Yamamoto A (2015) Effects of non-amputative wide local excision on the local control and prognosis of in situ and invasive subungual melanoma. J Dermatol 42:861–866
Nakamura Y, Tanaka K, Shibata T, Mizusawa J, Mizutani T, Fukuda H, Tsutsumida A, Namikawa K, Takahashi A, Fujisawa T, Yoshikawa S, Matsushita S, Yamazaki N (2018) Confirmatory trial of non-amputative digit preservation surgery in subungual melanoma: JCOG1602 (J-NAIL study). J Clin Oncol 36:515S, abstr TPS9607
Namikawa K, Yamazaki N (2011) Sentinel lymph node biopsy guided by indocyanine green fluorescence for cutaneous melanoma. Eur J Dermatol 21:184–190
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Melanoma Version2.2018-January 19. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
Oh BH, Lee SH, Nam KA, Lee HB, Chung KY (2013) Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot. Br J Dermatol 168:333–338
Ohn J, Choe YS, Mun JH (2016) Dermoscopic features of nail matrix nevus (NMN) in adults and children: a comparative analysis. J Am Acad Dermatol 75:535–540
Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–444
Paolino G, Bekkenk MW, Didona D, Eibenschutz L, Richetta AG, Cantisani C, Viti G, Carbone A, Buccini P, De Simone P, Ferrari A, Scali E, Calvieri S, Silipo V, Cigna E, Viti GP, Bottoni U (2016) Is the prognosis and course of acral melanoma related to site-specific clinicopathological features? Eur Rev Med Pharmacol Sci 20:842–848
Phan A, Touzet S, Dalle S, Ronger-Savle S, Balme B, Thomas L (2006) Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol 155:561–569
Piliang MP (2011) Acral lentiginous melanoma. Clin Lab Med 31:281–288
Pizzichetta MA, Talamini R, Stanganelli I, Puddu P, Bono R, Argenziano G, Veronesi A, Trevisan G, Rabinovitz H, Soyer HP (2004) Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol 150:1117–1124
Polom K, Murawa D, Rho YS, Spychala A, Murawa P (2012) Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. Br J Dermatol 166:682–683
Rashid M, Hussain SS, Aslam R, Illahi I (2003) A comparison of two fasciocutaneous flaps in the reconstruction of defects of the weight-bearing heel. J Coll Physicians Surg Pak 13:216–218
Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS (2017) Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Lab Investig 97:130–145
Rayatt SS, Dancey AL, Davison PM (2007) Thumb subungual melanoma: is amputation necessary? J Plast Reconstr Aesthet Surg 60:635–638
Reed RJ (1976) Acral lentiginous melanoma. Wiley, New York
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, Mcneil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
Saida T, Koga H, Uhara H (2011) Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol 38:25–34
Saldanha G, Potter L, Daforno P, Pringle JH (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12:4499–4505
Serpell JW, Carne PW, Bailey M (2003) Radical lymph node dissection for melanoma. ANZ J Surg 73:294–299
Shaw JH, Koea JB (1988) Acral (volar-subungual) melanoma in Auckland, New Zealand. Br J Surg 75:69–72
Shim JH, Shin HT, Park J, Park JH, Lee JH, Yang JM, Kim DH, Jang KT, Lee DY (2017) Mutational profiling of acral melanomas in Korean populations. Exp Dermatol 26:883–888
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122:3354–3362
Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48:94–100
Smock ED, Barabas AG, Geh JL (2010) Reconstruction of a thumb defect with Integra following wide local excision of a subungual melanoma. J Plast Reconstr Aesthet Surg 63:e36–e37
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199
Stoffels I, Von Der Stuck H, Boy C, Poppel T, Korber N, Weindorf M, Dissemond J, Schadendorf D, Klode J (2012) Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology. J Dtsch Dermatol Ges 10:51–57
Sureda N, Phan A, Poulalhon N, Balme B, Dalle S, Thomas L (2011) Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review. Br J Dermatol 165:852–858
Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J (2016) Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature. Clin Epidemiol 8:109–122
Takata M, Lin J, Takayanagi S, Suzuki T, Ansai S, Kimura T, Cerroni L, Saida T (2007) Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol 156:1287–1294
Takematsu H, Obata M, Tomita Y, Kato T, Takahashi M, Abe R (1985) Subungual melanoma. A clinicopathologic study of 16 Japanese cases. Cancer 55:2725–2731
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074
Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tuting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C (2018) Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol 178:443–451
Teramoto Y, Nakamura Y, Sato S, Yamazaki N, Yamamoto A (2016) Low Probability of Lymphatic Drainage to Cloquet's Node Is of Limited Value as Indicator for Pelvic Lymph Node Dissection in Patients with Lower Limb Melanoma. Lymphat Res Biol 14:109–114
Thomas JM, Newton-Bishop J, A’hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O’neill T, Ruka W, Bliss JM, United Kingdom Melanoma Study, G., British Association of Plastic, S. & Scottish Cancer Therapy, N (2004) Excision margins in high-risk malignant melanoma. N Engl J Med 350:757–766
Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM (2014) MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer 13:45
Van Der Ploeg IM, Kroon BB, Valdes Olmos RA, Nieweg OE (2009) Evaluation of lymphatic drainage patterns to the groin and implications for the extent of groin dissection in melanoma patients. Ann Surg Oncol 16:2994–2999
Vermeeren L, Van Der Ploeg IM, Olmos RA, Meinhardt W, Klop WM, Kroon BB, Nieweg OE (2010) SPECT/CT for preoperative sentinel node localization. J Surg Oncol 101:184–190
Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, Bufalino R, Craig P, De Marsillac J, Durand JC, Et AL (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318:1159–1162
Wada M, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M, Uchi H (2017) Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. J Dermatol 44:932–938
Wang Y, Zhao Y, Ma S (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16:691
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or – naive melanoma. J Clin Oncol 31:4311–4318
Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, Oashi K, Ogawa T, Hayashi A, Nakamura N, Tsuta K (2015) BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res 25:9–14
Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, Kim KM (2011) KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 119:330–335
Zebary A, Omholt K, Vassilaki I, Hoiom V, Linden D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J (2013) KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci 72:284–289
Zhang N, Wang L, Zhu GN, Sun DJ, He H, Luan Q, Liu L, Hao F, Li CY, Gao TW (2014) The association between trauma and melanoma in the Chinese population: a retrospective study. J Eur Acad Dermatol Venereol 28:597–603
Zhou QM, Li W, Zhang X, Chen YB, Chen XC, Guan YX, Ding Y, Wen XZ, Xia Q, Zhou Q, Peng RQ, Hou JH, Zhu XF, Zeng YX, Zhang XS (2012) The mutation profiles of common oncogenes involved in melanoma in southern China. J Invest Dermatol 132:1935–1937
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Teramoto, Y., Martinez-Said, H., Guo, J., Garbe, C. (2019). Acral Lentiginous Melanoma. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-46029-1_67-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-46029-1_67-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46029-1
Online ISBN: 978-3-319-46029-1
eBook Packages: Springer Reference MedicineReference Module Medicine